Want to join the conversation?
During 4Q15, $DNB recorded an impairment charge of $6.7MM in its Americas segment related to technology and software assets associated with certain in-process projects for the back-office supporting system. During FY15, $DNB recorded a loss of $37.5MM related to the divestiture of its business in ANZ based on Level II fair value inputs.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.